GHK-Cu (Copper Peptide)

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is an endogenous tripeptide that naturally chelates copper ions and is found in human plasma, saliva, and urine. It was first identified by Loren Pickart in 1973 and belongs to the copper peptide class — a small category of peptides defined by their ability to coordinate divalent copper into a biologically active complex. Unlike synthetic research peptides with no endogenous analog, GHK-Cu is a molecule the human body actually produces, with plasma concentrations declining measurably with age: from approximately 200 ng/mL in young adults to roughly 80 ng/mL in older populations. This age-related decline has made it a point of interest in longevity-oriented research, though causality between falling GHK-Cu levels and aging phenotypes has not been established in controlled human studies.

Research into GHK-Cu's mechanism of action describes a remarkably wide range of proposed biological activities. Studies in cell culture and animal models suggest it stimulates fibroblast proliferation and collagen synthesis, activates superoxide dismutase and other antioxidant pathways, promotes angiogenesis, and modulates TGF-beta signaling involved in wound contraction. A 2012 gene expression analysis by Pickart and colleagues, using the Broad Institute's Connectivity Map dataset, reportedly identified GHK-Cu as influencing the expression of over 4,000 human genes — a finding that is frequently cited in pro-GHK-Cu literature but should be interpreted cautiously, as gene expression changes in computational datasets do not directly translate to functional clinical outcomes. The copper-binding component appears essential: dephosphorylated or copper-free analogs show substantially reduced activity in most assay models.

The evidence base is meaningfully tiered. Human clinical evidence is primarily confined to dermatological applications: several small randomized controlled trials (typically 20–60 participants, durations of 8–12 weeks) have examined topical GHK-Cu formulations for skin parameters including wrinkle depth, skin laxity, and collagen density, with results generally favoring GHK-Cu over vehicle control, though blinding quality and industry funding sources warrant appropriate skepticism. Injectable GHK-Cu research in humans is sparse and largely anecdotal; the injectable use-case that circulates in biohacker communities is almost entirely extrapolated from animal wound-healing data and in vitro fibroblast studies. Animal models — predominantly rodent wound healing and alopecia models — show more consistent positive findings, including accelerated wound closure, increased vessel density, and promotion of hair follicle cycling. These results are promising but cannot be directly transposed to human systemic use. User self-reports from online communities describe applications ranging from subcutaneous injection at wound sites to intranasal administration for potential CNS effects, but these reports lack any systematic collection methodology and should be treated as hypothesis-generating at best.

Dosing ranges reported in research contexts vary considerably by application and route. Topical cosmetic formulations have used concentrations ranging from 0.1% to 2% GHK-Cu by weight, applied once or twice daily in published dermatological trials. Injectable doses reported in preclinical animal studies range broadly; human injectable use reported anecdotally in research communities often cites 1–2 mg per injection, subcutaneous, several times per week, but this range is drawn from user forums rather than controlled human trial data. This information is reported strictly in a research context and constitutes no dosing recommendation whatsoever — any decision to administer GHK-Cu via any route should involve a qualified medical professional and is outside the scope of this publication.

For educational purposes only: GHK-Cu occupies an unusual regulatory position. As an endogenous human peptide, it is not classified as a controlled substance in the United States, United Kingdom, EU member states, or Australia. In the US, it exists as an unregulated research chemical when sold for non-therapeutic purposes; it is not FDA-approved for any indication. Topical cosmetic products containing GHK-Cu are legal to sell in most jurisdictions under cosmetics regulation, but injectable preparations sold for human use occupy a legally grey area. Sourcing considerations for research-grade GHK-Cu should prioritize vendors providing HPLC and mass spectrometry COAs confirming peptide identity, purity above 98%, and copper chelation verification — the latter being particularly important since the biological activity depends on the intact copper complex. Absence of a verifiable COA from an accredited third-party laboratory is a significant red flag regardless of vendor claims.